November 8, 2022
Minneapolis, MN | OneOme, a leading pharmacogenomic and precision medicine company, has signed a contract with Hennepin Healthcare to provide pharmacogenetic (PGx) testing for some of their patients. PGx testing and results may prevent adverse drug events and encourage the use of therapies tailored to a patient’s genetic makeup and have a high applicability to pain management, cardiology, oncology, and mental/behavioral health.
Over 5 billion prescriptions are filled each year.1 However, not all drugs are effective for all people. In fact, positive response rates for many drugs are only 50-75%.2 One of the factors that can help explain this variability is an individual patient’s DNA, which may affect drug metabolism (pharmacokinetics), mechanism of action (pharmacodynamics), and drug toxicity.
James Kelley, MD, PhD, Chief Medical Officer at OneOme, said, “We are excited to collaborate with Hennepin Healthcare to bring access, awareness and education for PGx to both patients and providers. Using OneOme’s RightMed® Test, Hennepin Healthcare can enhance precision health care for their patients.”
Co-founded by Mayo Clinic, OneOme is a Minneapolis, Minnesota-based precision medicine company focused on bringing high-quality pharmacogenomics (PGx) into patient care. With a belief that PGx holds the potential to make a positive, appreciable difference in the lives of patients, OneOme works closely with their health care partners to help realize these benefits across the healthcare ecosystem.
For media inquiries:
Natalie Slack
(612) 895-5663
www.oneome.com
